TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068)

CalpurbatugPositive

AI Analysis

Summary

Trellis Bioscience raised $9 million in funding to advance clinical development of Calpurbatug (TRL1068), a novel monoclonal antibody therapy being evaluated for prosthetic joint infections.

Importance:5/10

Sentiment:

0.50

fundingclinical developmentmonoclonal antibodyprosthetic joint infections

Related Companies

$BHIC

Read the original article

Published by PR Newswire Biotech on July 16, 2026 9:33 PM

Read Original